Amgen dips ahead of Q3 earnings
AMGN•Amgen shares fell 0.5% ahead of its Q3 results, due after the closing bell. Analysts expect revenue of $10.07 billion, up 5%, and adjusted EPS of $5.79, compared with $5.64 a year earlier.
1. Earnings expectations
Investors are watching sales of Amgen’s growth drugs and pipeline updates, including its experimental obesity drug MariTide and cancer drug Imdelltra. Amgen has met or beaten EPS estimates for at least eight consecutive quarters; its most recent revenue miss was in Q3 2024.
